Altimmune said its Q3 2026 update keeps the focus on building a liver franchise around its investigational 1:1 glucagon/GLP-1 dual agonist. The statement gave n

Altimmune said its Q3 2026 update keeps the focus on building a liver franchise around its investigational 1:1 glucagon/GLP-1 dual agonist. The statement gave no added financial detail, following earlier positive Phase 2 RECLAIM data and its NJ HQ move.